Key points are not available for this paper at this time.
Radiation therapy is used in the treatment of various cancers, and advancements in irradiation techniques have further expanded its applicability. For radiation oncologists, predicting adverse events remains a critical challenge, even with these technological advancements. Although numerous studies have been conducted to predict individual radiosensitivity, no biomarkers have been clinically applied thus far. This review focuses on γ-H2AX foci and chromosomal aberrations, providing an overview of their association with normal tissue toxicities.
Nishibuchi et al. (Wed,) studied this question.